NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT00838578 2024-04-26Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal CancerKyowa Kirin Co., Ltd.Phase 1/2 Terminated65 enrolled 7 charts